Skip to main content
SpringerLink
Log in

A case of unresectable locally advanced intrahepatic cholangiocarcinoma that achieved pathological complete response after gemcitabine and S1 chemotherapy

Clinical Journal of Gastroenterology volume 15, pages 1164–1168 (2022)Cite this article

Abstract

The standard chemotherapy for patients with unresectable cholangiocarcinoma is gemcitabine plus cisplatin, and gemcitabine plus S-1 (GS) chemotherapy is also reported to have similar effectiveness in Japan. However, the response rates of these two chemotherapies were modest, and no patients with intrahepatic cholangiocarcinoma (ICC) have shown a pathological complete response (pCR) following these chemotherapies. We report here the first case of an initially unresectable locally advanced ICC that achieved pCR following GS chemotherapy.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Hong JC, Jones CM, Duffy JP, et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch Surg. 2011;146:683–9.

    Article  PubMed  Google Scholar 

  2. Kato A, Shimizu H, Ohtsuka M, et al. Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study. Ann Surg Oncol. 2013;20:318–24.

    Article  PubMed  Google Scholar 

  3. Sumiyoshi T, Shima Y, Okabayashi T, et al. Chemoradiotherapy for initially unresectable locally advanced cholangiocarcinoma. World J Surg. 2018;42:2910–8.

    Article  PubMed  Google Scholar 

  4. Leonard GD, O’Reilly EM. Biliary tract cancers: current concepts and controversies. Expert Opin Pharmacother. 2005;6:211–23.

    Article  PubMed  Google Scholar 

  5. Miyakawa S, Ishihara S, Horiguchi A, et al. Biliary tract cancer treatment: 5548 results from the biliary tract cancer statistics registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg. 2009;16:1–7.

    Article  PubMed  Google Scholar 

  6. Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996;224:463–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Nathan H, Aloia TA, Vauthey JN, et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2009;16:14–22.

    Article  PubMed  Google Scholar 

  8. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. ABC-02 trial Investigators. N Engl J Med. 2010;362:1273–81.

    Article  CAS  PubMed  Google Scholar 

  9. Morizane C, Okusaka T, Mizusawa J, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol. 2019;30:1950–8.

    Article  CAS  PubMed  Google Scholar 

  10. Lu J, Li B, Li FY, et al. Long-term outcome and prognostic factors of intrahepatic cholangiocarcinoma involving the hepatic hilus versus hilar cholangiocarcinoma after curative-intent resection: should they be recognized as perihilar cholangiocarcinoma or differentiated? Eur J Surg Oncol. 2019;45:2173–9.

    Article  PubMed  Google Scholar 

  11. Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol. 2019;5:824–30.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Kanai M, Hatano E, Kobayashi S, et al. A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002). Cancer Chemother Pharmacol. 2015;75:293–300.

    Article  CAS  PubMed  Google Scholar 

  13. Abudalou M, Vega EA, Kondratiev S, et al. Complete pathological response to neoadjuvant chemoimmunotherapy in a patient with metastatic intrahepatic cholangiocarcinoma with high tumor mutational burden. Cureus. 2021;5(13): e20187.

    Google Scholar 

  14. Matsubara T, Nishida T, Tomimaru Y, et al. Histological complete response in a patient with advanced biliary tract cancer treated by gemcitabine/cisplatin/S-1 combination chemotherapy: a case report. Mol Clin Oncol. 2016;5:757–61.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Kato A, Shimizu H, Ohtsuka M, et al. Downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer patients treated with gemcitabine plus cisplatin combination therapy followed by radical surgery. Ann Surg Oncol. 2015;22(Suppl 3):S1093–9.

    Article  PubMed  Google Scholar 

  16. Kobayashi H, Murakami Y, Uemura K, et al. Human equilibrative nucleoside transporter 1 expression predicts survival of advanced cholangiocarcinoma patients treated with gemcitabine-based adjuvant chemotherapy after surgical resection. Ann Surg. 2012;256:288–96.

    Article  PubMed  Google Scholar 

  17. Sasaki H, Murakami Y, Uemura K, et al. Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy. Br J Cancer. 2014;111:1275–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II keynote-158 study. J Clin Oncol. 2020;38:1–10.

    Article  CAS  PubMed  Google Scholar 

  19. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Lee V, Murphy A, Le DT, et al. Mismatch repair deficiency and response to immune checkpoint blockade. Oncologist. 2016;21:1200–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Akagi K, Oki E, Taniguchi H, et al. The real-world data on microsatellite instability status in various unresectable or metastatic solid tumors. Cancer Sci. 2021;112:1105–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Eguchi S, Shinkawa H, Sato Y, et al. Durable response after discontinuation of pembrolizumab therapy for intrahepatic cholangiocarcinoma: a case report. Clin J Gastroenterol. 2021;14:858–65.

    Article  PubMed  Google Scholar 

  23. Toshida K, Itoh S, Yoshizumi T. Efficacy of pembrolizumab in microsatellite instability-high locally advanced cholangiocarcinoma: a case report. Clin J Gastroenterol. 2021;14:1459–63.

    Article  PubMed  Google Scholar 

  24. Kai Y, Ikezawa K, Takada R, et al. Success rate of microsatellite instability examination and complete response with pembrolizumab in biliary tract cancer. JGH Open. 2021;5:712–6.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Abudalou M, Vega EA, Kondratiev S, et al. Complete pathological response to neoadjuvant chemoimmunotherapy in a patient with metastatic intrahepatic cholangiocarcinoma with high tumor mutational burden. Cureus. 2021;13: e20187.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, 1‐2‐3 Kasumi, Minami‐ku, Hiroshima, 734‐8551, Japan

    Tatsuaki Sumiyoshi, Kenichiro Uemura, Ryuta Shintakuya, Kenjiro Okada, Hiroyuki Otsuka & Shinya Takahashi

  2. Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan

    Masahiro Serikawa, Yasutaka Ishii & Tomofumi Tsuboi

  3. Department of Anatomical Pathology, Hiroshima University, Hiroshima, Japan

    Koji Arihiro

Authors
  1. Tatsuaki Sumiyoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenichiro Uemura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ryuta Shintakuya
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kenjiro Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiroyuki Otsuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masahiro Serikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yasutaka Ishii
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tomofumi Tsuboi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Koji Arihiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shinya Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenichiro Uemura.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Human/animal rights

All procedures performed in this study involving human participants were in accordance with the institutional ethics committee and with the 1964 Helsinki Declaration and its later amendments.

Informed consent

Informed consent was obtained from the patient included in this study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sumiyoshi, T., Uemura, K., Shintakuya, R. et al. A case of unresectable locally advanced intrahepatic cholangiocarcinoma that achieved pathological complete response after gemcitabine and S1 chemotherapy. Clin J Gastroenterol 15, 1164–1168 (2022). https://doi.org/10.1007/s12328-022-01700-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12328-022-01700-x

Keywords

search

Navigation